Nitroxolină Mip (Nitroxoline)

Nitroxoline, the active ingredient in Nitroxolină Mip, is a quinoline derivative antibacterial presented as an oral tablet for oral use. It treats uncomplicated urinary tract infections, including cystitis, in adult patients. GNH USA supplies Nitroxolină Mip as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nitroxolină Mip is used to manage bacterial infections of the urinary tract. - Uncomplicated urinary tract infection: eliminates causative bacteria and relieves dysuria and frequency. - Cystitis: treats bladder infection, reducing inflammation and promoting symptom resolution. - Acute uncomplicated cystitis: provides rapid bacterial clearance and symptom improvement.

Nitroxolină Mip may cause adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Vomiting: occasional episodes after dosing. - Abdominal pain: cramp‑like discomfort in the gastrointestinal tract. - Headache: transient dull or throbbing pain. - Rash: mild skin erythema or pruritus. - Altered taste: metallic or bitter sensation.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction with airway compromise. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Neutropenia: marked reduction in white blood cells. - Thrombocytopenia: low platelet count leading to bleeding risk. - Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement. - Interstitial nephritis: inflammation of kidney interstitium causing renal impairment.

Before prescribing Nitroxolină Mip, clinicians should consider several safety aspects. - Renal function: evaluate creatinine clearance in patients with kidney disease. - Hepatic function: monitor liver enzymes in individuals with liver impairment. - Pregnancy: use only if the potential benefit justifies the unknown risk to the fetus. - Elderly patients: start at the lowest effective dose and monitor for toxicity. - Concomitant medications: review all drugs for possible interactions. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Nitroxolină Mip can interact with other medicines, requiring careful assessment.

Major Interactions (Avoid): - Nephrotoxic agents (e.g., aminoglycosides): may increase risk of kidney injury. - Strong metal chelators (e.g., deferoxamine): can reduce nitroxoline absorption and efficacy. - Co‑administration with other quinolone antibiotics: risk of additive toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may heighten gastrointestinal irritation. - Warfarin: potential enhancement of anticoagulant effect, requiring INR monitoring. - Diuretics: possible electrolyte disturbances; monitor serum levels.